Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32748-32760

  Koch, Andreas ^a   Lang, Sven Arke ^a   Wild, Peter Johannes ^b   Gantner, Susanne ^a   Mahli, Abdo ^a   Spanier, Gerrit ^a   Berneburg, Mark ^a   Müller, Martina ^a   Bosserhoff, Anja Katrin ^c   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

GLUT1; Glycolysis; JNK; Melanoma; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GLUCOSE TRANSPORTER 1; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WZB 117; HYDROXYBENZOIC ACID DERIVATIVE; MMP2 PROTEIN, MOUSE; SLC2A1 PROTEIN, HUMAN; SLC2A1 PROTEIN, MOUSE; STRESS ACTIVATED PROTEIN KINASE; WZB117;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL LINE; METASTASIS POTENTIAL; MOUSE; MURINE MODEL; NONHUMAN; PROTEIN EXPRESSION; TISSUE MICROARRAY; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MELANOMA, EXPERIMENTAL; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYDROXYBENZOATES; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; MELANOMA, EXPERIMENTAL; MIDDLE AGED; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84946083687     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4977     Document Type: Article

References (53)

1. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370:599-609.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19:3622-3634.
3. Leiter U, Eigentler T and Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014; 810:120-140.
4. Tronnier M and Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014; 6:349-356.
5. Kim JW and Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66:8927-8930.
6. Brahimi-Horn MC, Chiche J and Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol. 2007; 19:223-229.
7. Airley RE and Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007; 53:233-256.
8. Medina RA and Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002; 35:9-26.
9. Amann T and Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert opinion on therapeutic targets. 2009; 13:1411-1427.
10. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R and West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer. 2003; 89:870-876.
11. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ and Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer. 2004; 40:503-507.
12. Younes M, Lechago LV and Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996; 2:1151-1154.
13. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A and Burstein DE. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83:34-40.
14. Nagarajah J, Grabellus F, Schmid K, Bockisch A and Sheu S. GLUT1 expression, tumor proliferation, and iodine/FDG-uptake in thyroid cancer with emphasis on poorlydifferentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2011; 38:S111-S112.
15. Park SG, Lee JH, Lee WA and Han KM. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol. 2012; 39:1167-1172.
16. Yamada K and Brink I. Factors influencing [F-18]. J Dermatol. 2005.
17. Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D and Leeper DB. Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res. 2002; 12:35-43.
18. Baer SC, Casaubon L and Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol. 1997; 37:575-577.
19. Slominski A, Kim TK, Brozyna AA, Janjetovic Z, Brooks DL, Schwab LP, Skobowiat C, Jozwicki W and Seagroves TN. The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways. Arch Biochem Biophys. 2014.
20. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fassler R and BosserhoffAK. Downregulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009; 206:221-232.
21. Ebelt ND, Cantrell MA and Van Den Berg CL. c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. Genes Cancer. 2013; 4:378-387.
22. Kappelmann M, BosserhoffA and Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. Eur J Cell Biol. 2014; 93:76-81.
23. Schmidt J, Riechers A, Stoll R, Amann T, Fink F, Spruss T, Gronwald W, Konig B, Hellerbrand C and BosserhoffAK. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS One. 2012; 7:e37941.
24. Amann T and Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009; 13:1411-1427.
25. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J and Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012; 11:1672-1682.
26. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Scholmerich J, Oefner PJ, Kreutz M, BosserhoffAK and Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009; 174:1544-1552.
27. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y and Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998; 11:437-443.
28. Jun YJ, Jang SM, Han HL, Lee KH, Jang KS and Paik SS. Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. World J Gastroenterol. 2011; 17:1866-1873.
29. Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM and Bigotti G. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res. 2008; 27:34.
30. Ito H, Duxbury M, Zinner MJ, Ashley SW and Whang EE. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004; 136:548-556.
31. Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA and Whiteside TL. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007; 43:796-803.
32. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, Ichihara T, Kuroda Y, Maeda S and Kasuga M. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001; 37:204-209.
33. Liu T, Kishton RJ, Macintyre AN, Gerriets VA, Xiang H, Liu X, Dale Abel E, Rizzieri D, Locasale JW and Rathmell JC. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis. 2014; 5:e1470.
34. Fumarola C, Caffarra C, La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Galvani E, Generali D, Petronini PG and Bonelli MA. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res Treat. 2013; 141:67-78.
35. Kerkela E and Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003; 12:109-125.
36. Kamyab-Hesari K, Mohtasham N, Aghazadeh N, Biglarian M, Memar B and Kadeh H. The expression of MMP-2 and Ki-67 in head and neck melanoma, and their correlation with clinic-pathologic indices. J Cancer Res Ther. 2014; 10:696-700.
37. Shaverdashvili K, Wong P, Ma J, Zhang K, Osman I and Bedogni B. MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1. Pigment Cell Melanoma Res. 2014; 27:287-296.
38. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S and Ronai Z. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007; 11:447-460.
39. Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, Civenni G, Sommer L, Moch H and Dummer R. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One. 2012; 7:e33571.
40. Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS and Morton DL. Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol. 2009; 16:2834-2839.
41. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC and Oyen WJ. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007; 55:79-87.
42. Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR and Hsueh S. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004; 45:22-29.
43. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T and Monden M. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006; 51:2198-2205.
44. Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N and Williams SP. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012; 2:22.
45. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B and KalffV. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging. 2008; 35:1786-1795.
46. Hofman MS, Constantinidou A, Acland K, Healy C, Harries M, O'Doherty M and Melanoma G. Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience. Nucl Med Commun. 2007; 28:902-906.
47. Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, Gnessi L, Griffin RJ, Minetti M and Malorni W. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. Int J Cancer. 2012; 131:E337-347.
48. Liu W, Fang Y, Wang XT, Liu J, Dan X and Sun LL. Overcoming 5-Fu Resistance of Colon Cells through Inhibition of Glut1 by the Specific Inhibitor WZB117. Asian Pac J Cancer Prev. 2014; 15:7037-7041.
49. Shimanishi M, Ogi K, Sogabe Y, Kaneko T, Dehari H, Miyazaki A and Hiratsuka H. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J Oral Pathol Med. 2013; 42:382-388.
50. He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, Dong X, Wang J, Jiang H and Sun X. Downregulating hypoxia-inducible factor-2alpha improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci. 2012; 103:528-534.
51. Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Scholmerich J and BosserhoffAK. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis. 2006; 27:64-72.
52. Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, Scholmerich J and Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009; 19:996-1005.
53. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, Kiefer P, BosserhoffAK and Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 2009; 100:646-653.